Related Experiment Videos

Beta-blockers for congestive heart failure

Matthew J Sorrentino1

  • 1University of Chicago, Pritzker School of Medicine, Department of Medicine, Section of Cardiology, 5841 S. Maryland Ave., MC 6080, Chicago, IL 60637, USA.

Comprehensive Therapy
|March 3, 2004
PubMed

Insights

Drug therapy targeting the renin-angiotensin and adrenergic nervous systems improves congestive heart failure (CHF) prognosis. Beta-adrenergic blocking drugs, previously avoided, now demonstrate improved survival rates in CHF patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) management traditionally focused on neurohormonal blockade.
  • Beta-adrenergic blocking drugs were historically contraindicated in CHF due to concerns about negative inotropic effects.

Purpose of the Study:

  • To evaluate the impact of drug therapies targeting the renin-angiotensin and adrenergic nervous systems on CHF prognosis.
  • To assess the role of beta-adrenergic blocking drugs in improving survival for CHF patients.

Main Methods:

  • Review of clinical studies and therapeutic guidelines.
  • Analysis of pharmacological interventions affecting the renin-angiotensin system.
  • Evaluation of outcomes associated with beta-adrenergic blockade in CHF populations.

Main Results:

  • Drug therapies targeting the renin-angiotensin and adrenergic nervous systems significantly improve CHF patient prognosis.
  • Beta-adrenergic blocking drugs, once contraindicated, are now proven to enhance survival in CHF.
  • Pharmacological modulation of these systems represents a cornerstone of modern CHF treatment.

Conclusions:

  • Targeted drug therapy offers substantial prognostic benefits for CHF patients.
  • Beta-adrenergic blockers are a vital component of CHF management, improving patient survival.
  • Understanding neurohormonal pathways is crucial for optimizing CHF treatment strategies.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...